Home›Velpatasvir And Sofosbuvir›Velpatasvir And Sofosbuvir + Omeprazole

Does Velpatasvir And Sofosbuvir Interact with Omeprazole?

CDI records a unknown classification for Velpatasvir And Sofosbuvir and Omeprazole. The stored summary is: Proton-pump inhibitors (e.g., omeprazole) Coadministration of omeprazole or other proton-pump inhibitors is not recommended. If it is considered medically necessary to coadminister, EPCLUSA should be administered with food and taken 4 hours before omeprazole 20 mg. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity
Unknown
Velpatasvir And Sofosbuvir Class
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Omeprazole Class
Proton Pump Inhibitor
Management
Consult your pharmacist
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Velpatasvir And Sofosbuvir and your doctor is considering prescribing Omeprazole (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Never stop or change either medication without first consulting your healthcare provider
💊 Velpatasvir And Sofosbuvir(Sofosbuvir And Velpatasvir)+💊 Omeprazole(Yosprala)

Severity & Interaction Details

ℹ️
unknown
Interaction documented — severity unclassified
The CDI record includes an interaction but its severity has not been classified.
Severity scale
MinorContra
On record
Yes
Drug A class
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Drug B class
Proton Pump Inhibitor
Source
FDA drug label - velpatasvir and sofosbuvir

What this means in plain English

Proton-pump inhibitors (e.g., omeprazole) Coadministration of omeprazole or other proton-pump inhibitors is not recommended. If it is considered medically necessary to coadminister, EPCLUSA should be administered with food and taken 4 hours before omeprazole 20 mg.

About Velpatasvir And Sofosbuvir and Omeprazole

Velpatasvir And Sofosbuvir is a Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor, while Omeprazole is a Proton Pump Inhibitor. Omeprazole is also sold under the brand name Yosprala. Velpatasvir And Sofosbuvir additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: FDA drug label - velpatasvir and sofosbuvir

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Velpatasvir And Sofosbuvir and Omeprazole against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations